KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Net Margin (2016 - 2025)

Historic Net Margin for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 5.2%.

  • Neogenomics' Net Margin rose 37100.0% to 5.2% in Q4 2025 from the same period last year, while for Dec 2025 it was 14.85%, marking a year-over-year decrease of 29300.0%. This contributed to the annual value of 14.85% for FY2025, which is 29300.0% down from last year.
  • Neogenomics' Net Margin amounted to 5.2% in Q4 2025, which was up 37100.0% from 14.45% recorded in Q3 2025.
  • Neogenomics' Net Margin's 5-year high stood at 63.61% during Q2 2021, with a 5-year trough of 42.17% in Q1 2022.
  • Moreover, its 5-year median value for Net Margin was 16.46% (2022), whereas its average is 14.47%.
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 714500bps in 2021, then tumbled by -918300bps in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Net Margin stood at 33.21% in 2021, then surged by 51bps to 16.36% in 2022, then surged by 44bps to 9.21% in 2023, then rose by 3bps to 8.91% in 2024, then skyrocketed by 42bps to 5.2% in 2025.
  • Its Net Margin was 5.2% in Q4 2025, compared to 14.45% in Q3 2025 and 24.87% in Q2 2025.